The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.

The levels of serum beta 2 microglobulin, blood urea concentration, serum creatinine, haemoglobin and performance status have been measured in 476 patients in the Medical Research Council's 4th trial for myelomatosis. Levels of serum beta 2 microglobulin were also subsequently measured in 208 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuzick, J., Cooper, E. H., MacLennan, I. C.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1985
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977159/
https://www.ncbi.nlm.nih.gov/pubmed/3893505
_version_ 1782135202245509120
author Cuzick, J.
Cooper, E. H.
MacLennan, I. C.
author_facet Cuzick, J.
Cooper, E. H.
MacLennan, I. C.
author_sort Cuzick, J.
collection PubMed
description The levels of serum beta 2 microglobulin, blood urea concentration, serum creatinine, haemoglobin and performance status have been measured in 476 patients in the Medical Research Council's 4th trial for myelomatosis. Levels of serum beta 2 microglobulin were also subsequently measured in 208 patients who achieved a stable "plateau" condition. Serum beta 2 microglobulin levels, uncorrected for serum creatinine, were found to be the single most powerful prognostic variable available at presentation. Multivariate analysis showed that only the addition of haemoglobin levels could improve upon this and the improvement, though statistically significant (P = 0.006), appeared to be of much less clinical value. The prognostic value of serum beta 2 microglobulin at plateau appeared to be equally large for a given difference in value, but the variability between patients was much less at that time. Serum beta 2 microglobulin would appear to be a key measurement for assessing the prognosis and response to treatment in patients with myelomatosis.
format Text
id pubmed-1977159
institution National Center for Biotechnology Information
language English
publishDate 1985
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19771592009-09-10 The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis. Cuzick, J. Cooper, E. H. MacLennan, I. C. Br J Cancer Research Article The levels of serum beta 2 microglobulin, blood urea concentration, serum creatinine, haemoglobin and performance status have been measured in 476 patients in the Medical Research Council's 4th trial for myelomatosis. Levels of serum beta 2 microglobulin were also subsequently measured in 208 patients who achieved a stable "plateau" condition. Serum beta 2 microglobulin levels, uncorrected for serum creatinine, were found to be the single most powerful prognostic variable available at presentation. Multivariate analysis showed that only the addition of haemoglobin levels could improve upon this and the improvement, though statistically significant (P = 0.006), appeared to be of much less clinical value. The prognostic value of serum beta 2 microglobulin at plateau appeared to be equally large for a given difference in value, but the variability between patients was much less at that time. Serum beta 2 microglobulin would appear to be a key measurement for assessing the prognosis and response to treatment in patients with myelomatosis. Nature Publishing Group 1985-07 /pmc/articles/PMC1977159/ /pubmed/3893505 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Cuzick, J.
Cooper, E. H.
MacLennan, I. C.
The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.
title The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.
title_full The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.
title_fullStr The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.
title_full_unstemmed The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.
title_short The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.
title_sort prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977159/
https://www.ncbi.nlm.nih.gov/pubmed/3893505
work_keys_str_mv AT cuzickj theprognosticvalueofserumbeta2microglobulincomparedwithotherpresentationfeaturesinmyelomatosis
AT coopereh theprognosticvalueofserumbeta2microglobulincomparedwithotherpresentationfeaturesinmyelomatosis
AT maclennanic theprognosticvalueofserumbeta2microglobulincomparedwithotherpresentationfeaturesinmyelomatosis
AT cuzickj prognosticvalueofserumbeta2microglobulincomparedwithotherpresentationfeaturesinmyelomatosis
AT coopereh prognosticvalueofserumbeta2microglobulincomparedwithotherpresentationfeaturesinmyelomatosis
AT maclennanic prognosticvalueofserumbeta2microglobulincomparedwithotherpresentationfeaturesinmyelomatosis

Ejemplares similares